Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

82.97 +1.52 (+1.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,135,832
Open 81.64
Bid (Size) 82.97 (3)
Ask (Size) 83.34 (1)
Prev. Close 81.45
Today's Range 81.19 - 83.14
52wk Range 57.16 - 89.74
Shares Outstanding 1,253,809,440
Dividend Yield 3.42%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis
A Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP),... 
Via Benzinga
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. As a result, there are still high rates of hospitalizations and COVID remains many... 
Via Benzinga

Performance

YTD
-2.83%
-2.83%
1 Month
+4.25%
+4.25%
3 Month
-3.35%
-3.35%
6 Month
+34.50%
+34.50%
1 Year
+39.56%
+39.56%

More News

Read More
ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash
Via Benzinga
Is It Time to Buy These Ultra-Cheap Dividend Stocks?
Via The Motley Fool
Gilead Sciences' Debt Overview
Via Benzinga
Gilead Exercises First License Option Under Agreement With Nurix Therapeutics
Via Benzinga
Gilead Sciences Unusual Options Activity
Via Benzinga
Why Are Cathie Wood's Ark ETFs Still Trailing Nasdaq Stocks?
Via Benzinga
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
Via The Motley Fool
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Bunge, Gilead Sciences And A Famous Chocolate Maker On CNBC's 'Final Trades'
Via Benzinga
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Via InvestorPlace
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
From Gilead Sciences, Inc.
Via Business Wire
A Bull Market Is Coming: Load Up On These 3 Cheap Stocks Today
Via The Motley Fool
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via TheNewswire.com
Exposures Product Safety
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via News Direct
Exposures Product Safety
Gilead's Flagship CAR T-cell Therapy Shows Improved Overall Survival In Pretreated Lymphoma Patients
Via Benzinga
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via Benzinga
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
Via Benzinga
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
From Gilead Sciences, Inc.
Via Business Wire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Via InvestorPlace
Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Why Shares of MacroGenics Jumped Thursday
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.